v3.26.3
EARNINGS (LOSS) PER SHARE
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE

NOTE 10 – EARNINGS (LOSS) PER SHARE

 

Basic earnings (loss) per common share (“EPS”) is based on the weighted average number of common shares outstanding during each period presented. Shares of unissued vested RSUs and RSAs are included in our calculation of basic weighted average common shares outstanding. Unvested RSUs and RSAs, convertible securities, warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from diluted earnings per share when the effects would be antidilutive.

 

The Company follows the provisions of ASC 260, Diluted Earnings per Share. In computing diluted EPS, basic EPS is adjusted for the assumed issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the entire period being presented.

 

The following table reconciles net income attributable to LifeMD, Inc. common stockholders from continuing operations and discontinued operations to basic and diluted earnings per share:

 

   2026   2025   2026   2025 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Net loss from continuing operations  $(4,469,713)  $(4,574,977)  $(20,585,088)  $(10,007,701)
Less: Preferred stock dividends   (776,563)   (776,563)   (2,329,688)   (2,329,688)
Net loss from continuing operations attributable to LifeMD, Inc. common stockholders   (5,246,276)   (5,351,540)   (22,914,776)   (12,337,389)
Net income from discontinued operations   -    935,013    -    4,821,519 
Less: Net income attributable to noncontrolling interests of discontinued operations   -    249,462    -    1,286,382 
Net income from discontinued operations attributable to LifeMD, Inc. common stockholders   -    685,551    -    3,535,137 
Net loss attributable to LifeMD, Inc. common stockholders  $(5,246,276)  $(4,665,989)  $(22,914,776)  $(8,802,252)

 

Basic loss per share is the same as diluted loss per share attributable to common stockholders for the three and nine months ended September 30, 2026 and 2025, because the inclusion of potential shares of common stock would have been anti-dilutive.

 

The following table discloses the securities that were not included in the computation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive:

 

   2026   2025   2026   2025 
  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
   2026   2025   2026   2025 
RSUs and RSAs   852,056    1,619,557    522,623    1,357,172 
Stock options   110,842    345,504    187,616    440,877 
Warrants   424,349    622,263    438,937    979,360 
Convertible long-term debt   -    -    -    671,141 
Total   1,387,247    2,587,324    1,149,176    3,448,550